Advice
Following a full submission
Candesartan (Amias) is accepted for use within NHS Scotland for the treatment of patients with heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction = 40%) as add-on therapy to ACE inhibitors or in patients who are unable to tolerate ACE inhibitors. Treatment with candesartan reduces mortality and hospitalisation due to heart failure. Candesartan may be used as a second-line agent in patients with chronic heart failure and LVEF = 40% following treatment with an ACE inhibitor and diuretic and with or without a betablocker.
Download detailed advice41KB (PDF)
Medicine details
- Medicine name:
- Candesartan cilexetil (Amias®)
- SMC ID:
- 161/05
- Indication:
- Heart failure and left ventricular systolic dysfunction
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 May 2005